In the last trading session, 1.38 million Legend Biotech Corp ADR (NASDAQ:LEGN) shares changed hands as the company’s beta touched 0.09. With the company’s per share price at $43.45 changed hands at $0.58 or 1.35% during last session, the market valuation stood at $7.96B. LEGN’s last price was a discount, traded about -61.4% off its 52-week high of $70.13. The share price had its 52-week low at $38.60, which suggests the last value was 11.16% up since then. When we look at Legend Biotech Corp ADR’s average trading volume, we note the 10-day average is 1.7 million shares, with the 3-month average coming to 953.31K.
Analysts gave the Legend Biotech Corp ADR (LEGN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.25. If we narrow down to specifics, the data shows that 0 out of 11 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended LEGN as a Hold, 11 felt it is a Buy and 0 rated the stock as Underweight. Legend Biotech Corp ADR’s EPS for the current quarter is expected to be -0.42.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Legend Biotech Corp ADR (NASDAQ:LEGN) trade information
Instantly LEGN was in green as seen at the end of in last trading. With action -12.54%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -27.79%, with the 5-day performance at -12.54% in the red. However, in the 30-day time frame, Legend Biotech Corp ADR (NASDAQ:LEGN) is -10.47% down. Looking at the short shares, we see there were 12.07 million shares sold at short interest cover period of 12.36 days.
The consensus price target for the stock as assigned by Wall Street analysts is 86, meaning bulls need an upside of 49.48% from its current market value. According to analyst projections, LEGN’s forecast low is 60 with 94 as the target high. To hit the forecast high, the stock’s price needs a -116.34% plunge from its current level, while the stock would need to soar -38.09% for it to hit the projected low.
Legend Biotech Corp ADR (LEGN) estimates and forecasts
Data shows that the Legend Biotech Corp ADR share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -7.67% over the past 6 months, a -0.68% in annual growth rate that is considerably lower than the industry average of 17.20%. Year-over-year growth is forecast to reach 105.70% up from the last financial year.
Consensus estimates given by 14 financial analysts project the company’s revenue in the current quarter to hit an average of 142.84M. 14 analysts are of the opinion that Legend Biotech Corp ADR’s revenue for the current quarter will be 176.93M. The company’s revenue for the corresponding quarters a year ago was 96.01M and 79.46M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 48.80%. The estimates for the next quarter sales put growth at 122.70%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -168.48%. The 2024 estimates are for Legend Biotech Corp ADR earnings to increase by 39.27%.
LEGN Dividends
Legend Biotech Corp ADR is expected to release its next quarterly earnings report in November.
PRICE T ROWE ASSOCIATES INC /MD/ holds the second largest percentage of outstanding shares, with 6.3126% or 11.49 million shares worth $508.86 million as of 2024-06-30.
